Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

PP5 enzyme decrease in neurons can cause cell death in Alzheimer's disease patients

A Purdue University researcher has discovered that the amount of an enzyme present in neurons can affect the mechanism thought to cause cell death in Alzheimer's disease patients and may have applications for other diseases such as stroke and heart attack.

8 Oct 2009

Study reveals large structural differences between natural prions and man-made synthetic analogs

A collaboration between scientists at Vanderbilt University and the University of California, San Francisco has led to the first direct information about the molecular structure of prions. In addition, the study has revealed surprisingly large structural differences between natural prions and the closest synthetic analogs that scientists have created in the lab.

7 Oct 2009

HDSA honors outstanding contributors against Huntington's Disease

The Huntington's Disease Society of America (HDSA), will recognize the outstanding contributions to improving the quality of life of people with Huntington's Disease (HD) by several individuals and two organizations at the 13th annual Guthrie Awards Dinner this Thursday.

7 Oct 2009

Research and development using stem cells from menstrual blood helps fight against breast cancer

Cryo-Cell International, a global leader in stem cell innovation, is proud to be making progress in the fight against breast cancer through research and development using stem cells from menstrual blood.

7 Oct 2009

New findings on Alzheimer's disease suggest a possible way for treatment

The action of a small protein that is a major villain in Alzheimer's disease can be counterbalanced with another brain protein, researchers at UT Southwestern Medical Center have found in an animal study.

7 Oct 2009

Merz publishes Phase III study results assessing the impact of NT 201 on muscle tone

Data results published this month in Clinical Neuropharmacology, revealed that Merz Pharmaceuticals' NT 201 (botulinum toxin type A free from complexing proteins), also known by the brand name Xeomin in Europe and Canada, was statistically significantly more efficacious than placebo for the treatment of patients with post-stroke upper limb spasticity.

7 Oct 2009

Biovail provides update on its Phase III program with pimavanserin for Parkinson’s disease psychosis

Biovail Corporation today provided an update on its Phase III program with pimavanserin for Parkinson’s disease psychosis (PDP), which is being pursued in collaboration with ACADIA Pharmaceuticals Inc. Following the announcement on September 1st of disappointing top-line results from the first Phase III PDP trial, Biovail and ACADIA remain committed to the successful development of pimavanserin and have established a development strategy that they believe will strengthen the PDP program.

7 Oct 2009

Update from ACADIA Pharmaceuticals regarding its Phase III program with pimavanserin

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today provided an update on its Phase III program with pimavanserin for Parkinson’s disease psychosis (PDP), which is being pursued in collaboration with Biovail Laboratories International SRL (“Biovail”), a subsidiary of Biovail Corporation.

6 Oct 2009

Study reveals information about molecular structure of prions

6 Oct 2009

Key defence mechanism used by the immune system against Listeria identified

A team of University of British Columbia microbiologists has identified a key defence mechanism used by the immune system against Listeria with strong implications for the future development of vaccines.

6 Oct 2009

Drivers with Parkinson's disease at greater risk of crashes on foggy days

Drivers with mild to moderate Parkinson's disease may be at higher risk of crashes on foggy days and other times of low visibility. The research, involving a driving simulation test, is published in the October 6, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology.

6 Oct 2009

GVK Biosciences and Quantitative Solutions to develop and market clinical trial outcome databases

GVK Biosciences (GVK BIO), Asia’s leading integrated research services provider and Quantitative Solutions (QS), a modeling and simulation (M&S) consultancy to the pharmaceutical and biotech industry, announced a strategic partnership to develop and market clinical trial outcome databases.

5 Oct 2009

BUSM's geriatrics clerkship meets all the ambulatory core geriatric competencies

As the population ages, it is imperative that medical students are prepared to treat older adults, regardless of their specialty. Researchers at Boston University School of Medicine (BUSM) report that an interdisciplinary multisite fourth-year geriatrics clerkship, has successfully met all the ambulatory core geriatric competencies as outlined by the Association of American Medical Colleges (AAMC) working group.

3 Oct 2009

Bradycardia more likely in patients taking cholinesterase inhibitors

People taking one of several drugs commonly prescribed to treat Alzheimer's disease are more likely to be hospitalized for a potentially serious condition called bradycardia than patients not taking these medications.

3 Oct 2009

Teens with chronic disease often have expensive, uncertain coverage

ABC News profiles teens living with chronic diseases, and examines their insurance coverage and the cost of such care. The article notes: "Chronic diseases affect 1 in 10 Americans and are the leading cause of disability, accounting for 70 percent of all deaths, according to the Centers for Disease Control and Prevention. They are also expensive."

3 Oct 2009

Budget cuts to affect low-income seniors

An 81-year-old San Francisco woman with dementia, little money and an equally aged caregiver sister who is suffering from cancer.

3 Oct 2009

Rush University receives grants to study how epigenomic changes define cognitive decline

The National Institutes of Health has awarded Rush University Medical Center approximately $5.5 million in grants to study how epigenetic changes - chemical modifications to genes that result from diet, aging, stress, or environmental exposures - define and contribute to memory formation and cognitive decline. Results from the studies could profoundly alter the way the medical community understands, diagnoses, and treats Alzheimer's disease, according to the researchers.

1 Oct 2009

UCF research team develops miniature diagnostic tool kit for dementia

With the risk of developing dementia growing at an alarming pace, a University of Central Florida research team is working with the Boston University School of Medicine to develop a miniature diagnostic toolkit in the hopes of stimulating earlier detection and treatment.

1 Oct 2009

Pfeiffer Treatment Center opens new Alzheimer’s care center in Illinois

Pfeiffer Treatment Center proudly announces that it has opened the Pfeiffer Center for Alzheimer’s care in Illinois.

1 Oct 2009

Streptococcal infection does not cause OCD or Tourette syndrome, says study

New research shows that streptococcal infection does not appear to cause or trigger Tourette syndrome or obsessive-compulsive disorder (OCD). The research is published in the September 30, 2009, online issue of Neurology®, the medical journal of the American Academy of Neurology.

1 Oct 2009

Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

PP5 enzyme decrease in neurons can cause cell death in Alzheimer's disease patients

Study reveals large structural differences between natural prions and man-made synthetic analogs

HDSA honors outstanding contributors against Huntington's Disease

Research and development using stem cells from menstrual blood helps fight against breast cancer

New findings on Alzheimer's disease suggest a possible way for treatment

Merz publishes Phase III study results assessing the impact of NT 201 on muscle tone

Biovail provides update on its Phase III program with pimavanserin for Parkinson’s disease psychosis

Update from ACADIA Pharmaceuticals regarding its Phase III program with pimavanserin

Study reveals information about molecular structure of prions

Key defence mechanism used by the immune system against Listeria identified

Drivers with Parkinson's disease at greater risk of crashes on foggy days

GVK Biosciences and Quantitative Solutions to develop and market clinical trial outcome databases

BUSM's geriatrics clerkship meets all the ambulatory core geriatric competencies

Bradycardia more likely in patients taking cholinesterase inhibitors

Teens with chronic disease often have expensive, uncertain coverage

Budget cuts to affect low-income seniors

Rush University receives grants to study how epigenomic changes define cognitive decline

UCF research team develops miniature diagnostic tool kit for dementia

Pfeiffer Treatment Center opens new Alzheimer’s care center in Illinois

Streptococcal infection does not cause OCD or Tourette syndrome, says study

Innovation in neuroscience drug discovery - eBook eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Innovation in neuroscience drug discovery - eBook eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Newsletters you may be interested in